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Introduction
High-grade serous ovarian cancer comprises approximately 40% of epithelial ovarian cancer cases and is the most aggressive histologic type (1) (2) (3) (4) . This type of cancer usually presents as advanced-stage disease at the time of diagnosis, because there are no symptoms present at the early stage and no reliable screening test for early detection (1) (2) (3) (4) . Patients with advanced-stage high-grade serous ovarian cancer generally undergo primary debulking surgery followed by platinum-taxane chemotherapy. However, 30-40% of patients recur within 12 months after the standard treatment, and the overall five-year survival rate remains at approximately 30% (5, 6) . Clinicopathological characteristics, such as the International Federation of Gynecology and Obstetrics (FIGO) stage, histological grade, and debulking status after primary surgery, are clinically considered important clinical prognostic indicators of ovarian cancer but are insufficient for predicting survival time.
The development of microarray technology has provided new insights into cancer diagnosis and treatment. Large-scale microarray studies in breast cancer have succeeded in clarifying five molecular subtypes based on gene expression profiles, and in developing genomic biomarker for predicting recurrence in early breast cancer (MammaPrint TM ; Agendia, Amsterdam, the Netherlands) (7, 8) . Thus, breast cancer treatment strategies are being stratified according to molecular characteristics. In contrast, there are no gene expression signatures with high accuracy and reproducibility for clinical diagnosis and management in patients with ovarian cancer because there is a paucity of ovarian cancer samples available for microarray analysis compared to breast cancer.
Although TP53 somatic mutation is present in almost all high-grade serous ovarian cancer and plays an important role in the pathogenesis (9,10), high-grade serous ovarian cancer exhibits much biological and molecular heterogeneity that should be considered when developing a novel therapeutic strategy for ovarian cancer (10, 11) .
In this study, we aimed to establish a novel system for predicting the prognosis of patients with advanced-stage high-grade serous ovarian cancer using large-scale microarray datasets (n=1,054) (10-13), leading to an optimal treatment based on molecular characteristics (14) .
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Clinical samples
Three hundred Japanese patients who were diagnosed with advanced-stage high-grade serous ovarian cancer between July 1997 and June 2010 were included in this study. All patients provided written informed consent for the collection of samples and subsequent analysis. Fresh frozen samples were obtained from primary tumor tissues during debulking surgery prior to chemotherapy. All patients with advanced-stage high-grade serous ovarian cancer were treated with platinum-taxane standard chemotherapy after surgery. In principle, patients were seen every 1 to 3 months for the first 2 years.
Thereafter, follow-up visits had an interval of 3 to 6 months in the third to fifth year, and 6 to 12 months in the sixth to tenth year. At every follow-up visit, general physical and gynecologic examinations were performed. CA125 serum levels were routinely determined.
Staging of the disease was assessed according to the criteria of the International Federation of Gynecology and Obstetrics (FIGO) (15) . Optimal debulking surgery was defined as less than 1cm of gross residual disease, and suboptimal debulking surgery was defined as more than 1 cm of residual disease. Progression-free survival time was calculated as the interval from primary surgery to disease progression or recurrence. Based on the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 (16) , disease progression was defined as at least a 20% increase in the sum of the diameters of target lesions, as unequivocal progression of existing non-target lesions, or as the appearance of one or more new lesions. Overall survival time was calculated as the interval from primary surgery to the death due to ovarian cancer.
The histological characteristics of surgically resected specimens, which were diagnosed as serous histologic type by two pathologists at each institute, were at first assessed on formalin-fixed and paraffin-embedded hematoxylin and eosin sections by eight gynecological pathologists who belong to department of pathology in four institutes (Niigata University, National Defense Medical Collage, Tottori University, Kagoshima City Hospital). Next, these sections were reviewed under 
Microarray experiments
Frozen tissues containing more than 70% tumor cells upon histological evaluation were used for RNA extraction. Total RNA was extracted from tissue samples as previously described (19) . Five hundred nanograms of total RNA were converted into labeled cRNA with nucleotides coupled to a cyanine 3-CTP (Cy3) (PerkinElmer, Boston, MA, USA) using the Quick Amp Labeling Kit, one-color (Agilent Technologies, Tokyo, Japan). Cy3-labeled cRNA (1.65 µg) was hybridized for 17 hours at 65°C to an Agilent Whole Human Genome Oligo Microarray (G4112F), which carries 60-mer probes to more than 40,000 human transcripts. The hybridized microarray was washed and then scanned in Plus 2.0 Array. GeneChips were washed and stained in the Affymetrix Fluidics Station 450, and scanned using GeneChip Scanner 3000 7G.
The MIAME-compliant microarray data were deposited into the Gene Expression Omnibus data repository (accession number GSE32062 and GSE32063).
Microarray Data analysis
We prepared two our microarray datasets [Japanese dataset A (n = 260) and B (n = 40)] and four publicly available large sample-sized (n>100) microarray datasets [TCGA dataset (http://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp) (11), Tothill's dataset (GSE9891) (12), Bonome's dataset (GSE26712) (13) , and Dressman's dataset (http://data.genome.duke.edu/platinum.php) (14) ] to discover predictive biomarkers. Clinical information of publicly available microarray datasets was cross-platform normalization ( Supplementary Fig. S1 ). Of 22,277 probes that were common among three Affymetrix platforms, 20,331 probes were selected to be in one to one relation between probe and gene. Using translation function based on Entrez Gene ID in GeneSpring GX 11.5, the 19, 704 transcripts that matched to the 20,331 probes of the Affymetrix platform were extracted from all transcripts on the Agilent platform. Considering differences in microarray platforms, coefficient of correlation (r) in each gene between two microarray platforms were measured. Using 10 ovarian cancer microarray data obtained from both Agilent Whole Human Genome Oligo Microarray and Affymetrix HG-U133Plus2.0 (GSE32062), 9,141 genes with high correlation (r > 0.8) were extracted.
After Median Rank Score analysis (20), we evaluated median value of each gene in both platforms and selected 3,553 genes with high correlation (r > 0.8) whose absolute value of subtracting median values between two platforms was less than 1. Similar analyses were performed using 16 breast cancer microarray data (GSE17700) (21) from both Affymetrix HG-U133Plus2.0 and HG-U133A.
From the resulting 1,746 genes, we removed 60 that were not flagged as "Detected" in more than 90% of the Japanese dataset A samples (n = 260), considering them to have either missing or uncertain expression signals. In addition, the data were normalized per gene in each dataset by transforming the expression of each gene to obtain a mean of 0 and standard deviation of 1 (Z-transformation) for the cross-platform study.
We analyzed Japanese dataset A as a "training set", Tothill's dataset as a "test set", and the other 4 datasets as "validation sets". We applied elastic net analysis (22) coefficient of each survival-related gene given by elastic net (α = 0.05) in the Japanese dataset A was also applied to calculate a prognostic index for each patient in five other datasets using the equation above. We classified all patients into the two groups (high-and low-risk groups) by the optimal cutoff value of the prognostic index in the Japanese dataset A. Patients were assigned to the "high-risk" group if their prognostic index was greater than or equal to cutoff value of prognostic index, whereas "low-risk" group was composed of cases with the prognostic indices that were less than cutoff value.
Because risk classification divided by cutoff value 0.1517 indicated a minimum P value (P = 1×10 -30 ) when logrank test was used to compare differences in overall survival between high-and low-risk groups in the Japanese dataset A, this value was determined as optimal cutoff value.
Both hierarchical clustering and non-negative factorization (NMF) algorithm (24) were used to assess the similarity of gene expression profiles among 126 survival-related genes. In the two major datasets (Japanese dataset A and TCGA dataset), we constructed a heat map with hierarchical clustering for both samples and genes using Cluster 3.0 (http://bonsai.hgc.jp/~mdehoon/software/cluster/software.htm). Correlation (centered) and complete linkage were selected on similarity metrics and clustering method, respectively. A heat map was visualized with Java TreeView (http://jtreeview.sourceforge.net/). NMF-consensus matrices averaging 50 connectivity matrices were computed at K=2-7 (as the number of subclasses modeled) for 126 genes. With genes appearing along both the horizontal and vertical axes of the consensus matrices, consistency in the gene-pair clusters was visualized. We determined the optimal number of gene clusters by the cophenetic correlation coefficient that provides a scalar summary of global clustering robustness across the consensus matrix in the Japanese dataset A and TCGA dataset.
We performed a volcano plot analysis to extract differentially expressed transcripts between high-and low-risk ovarian cancer groups using the two major datasets [Japanese dataset A (n = 260) and TCGA dataset (n = 319)]. When the volcano plot analysis was performed in GeneSpring GX 11.5 (Agilent Technologies), we used gene expression data prior to Z-transformation normalization (Fig. 3) .
on system to analyze networks and pathways for a set of genes. Q value was calculated using Fisher's exact test with the Benjamini and Hochberg correction (27) . Q value < 0.25 was considered as significant in GO, GSEA, and IPA.
SNP array experiments
We isolated genomic DNA from tumor tissues using a phenol-chloroform extraction method and from normal lymphocytes using the QIAamp DNA Blood Maxi Kit (Qiagen, Tokyo, Japan). SNP array experiments with the Genome-Wide Human SNP Array 6.0 (Affymetrix) were carried out at Niigata University (details in the Supplementary Methods). SNP array data were analyzed by using the Partek Genomic Suite 6.5 (Partek Inc., St. Louis, MO, USA) to investigate copy number variations in 30 genes involved in the antigen presentation pathway.
Immunoshitochemical analysis
A monoclonal anti-human CD8 antibody (M7103; 1:100; DAKO, Tokyo, Japan) was used for 
Results
The distribution of the clinical variables for each microarray dataset is shown in Table 1 . To compare the microarray datasets measured with four different platforms, 1,686 genes were selected ( Supplementary Fig. S1 ). An elastic net analysis (22) using 10-fold cross-validation on Japanese dataset A (training set, n = 260) identified a 126-gene signature for predicting overall survival in patents with advanced-stage high-grade serous ovarian cancer (Supplementary Table S1 ). After calculating the prognostic index for each sample from the 126-gene expression signature as reported previously (19), we divided the training set into high-and low-risk groups based on the optimal cutoff value (0.1517) of the prognostic index and verified the high predictive power of this risk microarray data was obtained from Affymetrix platforms and confirmed that this risk classification indicated similar results in the three datasets (Fig. 1C-E and Table 2 ). Furthermore, to exclude the influence of differences in microarray platforms, we prepared Japanese dataset B from the same platform as the training set. Despite the small sample size, our risk classification demonstrated a significant association with overall survival time in the Japanese dataset B (Fig. 1F and Table 2 ). This risk classification showed high predictive accuracy even though overall survival was capped at 60 months ( Supplementary Fig. S2 ) (10) . Moreover, the high-risk groups had shorter progression-free survival times compared to the low-risk groups in four microarray datasets with available progression-free survival times (Supplementary Fig. S3 ). In addition, we applied 193 overall survival related gene signature that have been recently reported by TCGA research networks (10) We next investigated the molecular characteristics of the 126-gene signature with both hierarchical clustering and NMF (24) analyses using the two major datasets (Japanese dataset A and TCGA dataset). Hierarchical clustering of the expression of 126 genes in the Japanese dataset A (n = 260) resulted in two gene clusters (cluster 1 and 2) (Fig. 2A) . Cluster 1 (outlined in yellow in Fig. 2A) comprised 23 genes, 22 of which were common genes in a small cluster of NMF class assignment for K = 2 ( Supplementary Fig. S5 ). Similarly, this gene cluster was seen both in hierarchical clustering and NMF analyses of TCGA dataset, and the 20 genes in TCGA's cluster were consistent with these 23 genes in cluster 1 ( Fig. 2B and Supplementary Fig. S5 ). GO analysis of these 23 genes revealed To clarify the biological significance of our risk classification based on the 126-gene signature in advanced-stage high-grade serous ovarian cancer, we examined differences in molecular biological characteristics between high-and low-risk groups. For subsequent analyses, all transcripts on each platform were used to avoid the previous gene number limitations, which were for the cross-platform study. We extracted the genes differentially expressed between the two groups by performing a volcano plot analysis using the two major datasets (Japanese dataset A and TCGA dataset) (Supplementary Table S3 ). Figure 3A shows that 1,109 and 1,381 transcripts were differentially expressed between the high-and low-risk groups in the Japanese dataset A and TCGA dataset, respectively. GO analysis of these transcripts indicated that 9 out of 20 top-ranked GO categories were common between both datasets and involved in the immune system (Table 3) .
To exclude the influence of cutoff in fold change or P value in volcano plot analysis, we re-evaluated differences in the biological characteristics between high-and low-risk groups using GSEA (26) . Four immunity-related GO categories (immune system response, immune response, defense response, and inflammatory response) were also included in the list of 20 top-ranked GO categories when GSEA was performed using 21,785 (Japanese dataset A) and 14,023 (TCGA dataset) transcripts prior to gene extraction (Supplementary Table S4 ).
Furthermore, possible functional relations among differentially expressed genes between high-and low-groups were investigated using pathway analysis. Of 20 top-ranked pathways notably enriched in 1,109 transcripts of the Japanese dataset A and 1,381 transcripts of the TCGA dataset, 14 pathways were common between both datasets (Supplementary Table S5 ). In particular, the antigen presentation pathway (Fig. 3B ) was the most significantly over-represented pathway in the two datasets (Japanese dataset A, Q = 2.0×10 -29 ; TCGA dataset, Q = 5.0×10 -14 ). In the antigen presentation pathway, 30 transcripts in this pathway were significantly down-regulated in the high-risk group (Fig. 3B and Supplementary Table S6 ). We further examined whether molecular defects of HLA class I antigen presentation machinery components were caused by structural alterations using SNP array data. Our SNP array data showed that genes of HLA class I antigen
Research. Table S6 ). In the TCGA dataset, only 10% of cases (24/242) had deletions in HLA class I genes. On the other hand, 89% of high-risk cases (55/62) without deletion in HLA class I genes showed significantly lower expressions in HLA class I genes compared with those in low-risk groups (Supplementary Fig. S6 ).
On the basis of this result, we assessed the status of tumor-infiltrating lymphocyte reflecting an immune response against ovarian cancer. By immunohistochemically staining for CD8-positive T lymphocytes in a subset of the Japanese dataset (n = 30), we revealed that the number of CD8 T lymphocytes infiltrating into tumor tissues was significantly decreased in the high-risk group (n = 10) compared with the low-risk group (n = 20) and was clearly correlated with the expression level of HLA class I genes ( Supplementary Fig. S7 ).
Discussion
In this study, we established a novel risk classification system based on the 126-gene expression signature for predicting overall survival time in patients with advanced-stage high-grade serous ovarian cancer. The significant association between our risk classification and overall survival time was indicated among the six microarray datasets.
In expression microarray analyses, there is a well-known "curse of dimensionality" problem that the number of genes is much larger than the number of samples. The curse of dimensionality leads to a concern about the reliability of the selected genes or an overfitting phenomenon, and using a large-scale microarray data is a simple and effective method to overcome this problem. From this theory, we planned a large-scale cross-platform study using four publicly available microarray datasets consisting of more than one hundred samples. To perform a cross-platform study, we took considerable care to reduce the influence of differences in microarray platforms using the Median Rank Score method and matching probes based on highly correlated expression (r>0.8) between the two platforms. As a result, this risk classification system showed a high predictive ability in the four microarray datasets from different platforms. Our risk classification was suitably fitting to Japanese dataset B despite the small sample size. This might reflect the same platform in the microarray experiments and similarity in clinical backgrounds between Japanese dataset A and B. Intriguingly, 193 survival-related gene signature that has been reported by TCGA research networks (10) was also significantly associated with overall survival in our large dataset ( Supplementary Fig.S4 ), and 5 genes (B4GALT5, CXCL9, ID4, MTRF1, and SLC7A11) were common between their and our gene signatures despite different analytical processes (Supplementary Table 2 ). These genes might contribute strongly to developing risk classification system for high-grade serous ovarian cancer patients.
We ascertained that alterations to the immune system in cancer cells are one of the most important factors affecting survival of patients with advanced-stage, high-grade serous ovarian cancer and that high-risk ovarian cancer was well characterized by the down-regulation of the antigen presentation pathway at the molecular level.
The two large-scale subclassification studies (10, 11) Previous findings (28) (29) (30) that the presence of tumor-infiltrating T lymphocytes is associated with long survival in ovarian cancer patients are consistent with the results from our comprehensive gene expression analysis using large-scale microarray data, suggests that the presence of immune responses to cancer cells would influence the biological phenotype of ovarian cancer.
Although several antigen-specific active immunotherapy studies have been conducted, the clinical benefit of this approach has not yet been shown in large randomized-controlled trials (31, 32) .
Previous reports (28, 33, 34) and our data indicated that defects in HLA class I antigen presentation machinery would decrease recruitment of tumor-infiltrating lymphocytes, leading to poor prognosis in cancer patients because of a reduction in antitumor immune activity. Therefore, up-regulation of HLA class I antigen presentation pathway might be one of efficient therapeutic approach for patients with high-risk serous ovarian cancer, especially when antigen-specific active immunotherapy is selected as a therapeutic strategy (35) .
Defects of HLA class I gene expression occurs at the genetic, epigenetic, transcriptional, and posttranscriptional levels, and are classified into the two main groups: reversible and irreversible defects (36) . Our data show that the frequency of deletion leading to irreversible defect of HLA class I gene expression was low in high-grade serous ovarian cancer. Only a few HLA class I gene mutations have been described thus far (36) . Down-regulation of antigen presentation machinery components such as TAP1/2 or B2M also result in reversible defects in HLA class I molecules (37) .
Interestingly, the expression levels of genes in the antigen presentation pathway were positively correlated in the Japanese dataset A (Supplementary Fig. S8 ). IFN-γ or other cytokines stimulation induces the expression of genes in the antigen presentation pathway (38) . Moreover, histone deacetylase (HDAC) inhibitors increase the expression of genes in the antigen presentation pathway such as TAP1/2 (39, 40) and B2M (41) in several cancer cells leading to up-regulating the antigen presentation pathway. In addition, HDAC inhibitors that are promising anticancer drugs show a synergistic effect with taxane or platinum drugs, which were used as standard adjuvant chemotherapy for ovarian cancer, both in vitro and in vivo (42, 43) . These genetic and epigenetic activations of the antigen presentation pathway might induce immune recognition of ovarian cancer cells and enhance antitumor immune responses.
In summary, our data suggest that this predictive biomarker based on the 126-gene signature could identify patients who should not expect long-term survival by standard treatment and that activation of the antigen presentation pathway in tumor cells is an important key in new therapeutic strategies for ovarian cancer. 
